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ABSTRACT
Introduction: Cigarette smoke contributes to a diverse
range of diseases including chronic obstructive
pulmonary disease (COPD), cardiovascular disorders
and many cancers. There currently is a need for
human challenge models, to assess the acute effects of
a controlled cigarette smoke stimulus, followed by
serial sampling of blood and respiratory tissue for
advanced molecular profiling. We employ precision
sampling of nasal mucosal lining fluid by absorption to
permit soluble mediators measurement in eluates.
Serial nasal curettage was used for transcriptomic
analysis of mucosal tissue.
Methods and analysis: Three groups of strictly
defined patients will be studied: 12 smokers with
COPD (GOLD Stage 2) with emphysema, 12 matched
smokers with normal lung function and no evidence of
emphysema, and 12 matched never smokers with
normal spirometry. Patients in the smoking groups are
current smokers, and will be given full support to stop
smoking immediately after this study. In giving a
controlled cigarette smoke stimulus, all patients will
have abstained from smoking for 12 h, and will smoke
two cigarettes with expiration through the nose in a
ventilated chamber. Before and after inhalation of
cigarette smoke, a series of samples will be taken from
the blood, nasal mucosal lining fluid and nasal tissue
by curettage. Analysis of plasma nicotine and
metabolites in relation to levels of soluble inflammatory
mediators in nasal lining fluid and blood, as well as
assessing nasal transcriptomics, ex vivo blood platelet
aggregation and leucocyte responses to toll-like
receptor agonists will be undertaken.
Implications: Development of acute cigarette smoke
challenge models has promise for the study of
molecular effects of smoking in a range of pathological
processes.
Ethics and dissemination: This study was approved
by the West London National Research Ethics
Committee (12/LO/1101). The study findings will be
presented at conferences and will be reported in peer-
reviewed journals.
BACKGROUND
There are profound causative and contribu-
tory effects of chronic cigarette smoking in a
range of disease processes, as well as consider-
able mortality.1 2 In order to understand the
changes in the lungs due to chronic smoking,
it is relevant to assess the immunological
responses to acute smoke exposure. Repetitive
acute effects of cigarette smoke in susceptible
individuals may lead to cumulative irreversible
damage.3 Despite cigarette smoking being the
Strengths and limitations of the study
▪ This model involves limited numbers of highly
selected individuals, and as such selection bias
will inevitably occur. However, in conjunction
with serial sampling in controlled conditions,
this enables discrimination of relatively small
changes in levels of cigarette smoke constituents
and the subsequent inflammatory response.
▪ It is possible to study acute effects of cigarette
smoke in a variety of smoking-related diseases.
In this way it may be possible to gain molecular
insight into the pathology of chronic obstructive
pulmonary disease, cardiovascular disease and
neoplasia.
▪ The specific categorisation of patients with
notable emphysema, who are not currently
taking any anti-inflammatory or disease modify-
ing interventions, will help reveal target pathway
nuances that drive oxidant-dependent chronic
disease.
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most important risk factor for the development of chronic
obstructive pulmonary disease (COPD) and a major con-
tributory inﬂuence in the development of cardiovascular
disease, the use of human cigarette challenge models has
been underutilised in the investigation of immune and
local inﬂuences on the disease.4 This is somewhat surpris-
ing, as we still know little about the mechanisms involved
in smoke-induced inﬂammation in man.
While several downstream effects of cigarette smoking
are common to all smokers, such as antioxidant gene acti-
vation and aryl hydrocarbon signalling, it is estimated
that only 13–50% of smokers actually develop COPD,5 6
and within this group, there is great clinical heterogen-
eity.2 The immunopathology of COPD is complex and
variable, involving the large airways (bronchitis), small
airways (bronchiolitis), lung interstitium (emphysema
and interstitial lung disease), pulmonary vasculature
(pulmonary artery hypertension) and systemic and car-
diovascular complications.7 There is also the added com-
plexity attributable to the innate immune response to
oxidants and microbes.8 9 Our group and others have
previously demonstrated that cigarette smoke (extract)
can activate human immune and respiratory epithelial
cells in vitro leading to the release of the proinﬂamma-
tory chemokine CXCL8.10–15 In addition, following
smoking, blood of smokers is ‘primed’ to activation ex
vivo by pathogen-associated molecular patterns (PAMPs)
including lipopolysaccharide (LPS).16 Most recently we
have performed a pilot transcriptomic study using
human monocytes stimulated in vitro and shown that
smoke activates and inhibits discrete groups of genes
involved in oxidant stress and inﬂammation.17 In add-
ition there have been individual genomic, transcriptomic
and metabolomic studies in cell-based18–24 and animal
models25 of smoking which have further deﬁned the role
of cigarette smoke as an inﬂammatory insult. However,
there is now a need for a multisystems-based approach in
man in vivo to truly advance our understanding of how
cigarette smoking induces inﬂammation.26
A protocol for a study of the effects of smoking in
patients with COPD has recently been reported by Lo
Tam Loi et al27 from Utrecht, Netherlands. This group
proposes the assessment of acute effects of smoking at
5 min after smoking three cigarettes, at 2 h, 24 h and
after a 6 week interval. They also propose assessment of
cross-sectional inﬂammatory responses in different
patient groups. In this study sampling from patients con-
sists of blood, sputum and exhaled breath condensate
(EBC); and they employ endobronchial sampling for
biopsy, epithelial lining ﬂuid and epithelial brushings.
Our group is currently conducting an in vivo model of
acute cigarette smoke inhalation challenge in smokers
with COPD and appropriate controls. Our study differs
in selection of patients, and having more deﬁned condi-
tions for cigarette smoke exposure. In addition, we have
an intensive sampling schedule over the 5 h following a
controlled cigarette smoke stimulus, with a focus on
blood and nasal non-invasive sampling, during which we
assess levels of nicotine and metabolites in relation to
proinﬂammatory effects. Such a study has thus far been
difﬁcult since access to human airway tissue and secre-
tion samples in a minimally invasive serial manner has
not previously been possible.
There has been recent progress in ﬁnding novel bio-
markers for COPD,28 29 and a focus on recognising new
phenotypes of COPD.30 GlaxoSmithKline has completed
a 3-year longitudinal study in 2180 patients with COPD
entitled ECLIPSE (Evaluation of COPD Longitudinally
to Identify Predictive Surrogate Endpoints).31 In terms
of the natural history of COPD it was found that sputum
neutrophil counts32 and EBC pH was not useful.33 EBC
has limitations of dilution and salivary contamination.34
In contrast, induced sputum contains many dead and
dying cells, making quantitation of levels of inﬂamma-
tory mediators problematic.
The nasal epithelium is the ﬁrst point in the respira-
tory system where cigarette smoke has contact with the
respiratory mucosa. As part of ‘the one airway concept’
that is well established in asthma, there is also consider-
able evidence for nasal involvement in COPD.35 36
Patients with COPD have chronic nasal symptoms and
impaired quality of life,37–39 with upper and lower airway
inﬂammation,40 and exacerbation of COPD is associated
with increased pan-airway inﬂammation.41 In addition,
young ‘healthy smokers’ have functional and inﬂamma-
tory changes in the nose and lower airways.42
For this reason our study is based on taking respiratory
samples from the nose by nasal absorption and curet-
tage. It has long been recognised that there is ‘one
airway’, with a strong functional and immunological rela-
tionship between the nose and the bronchi.43–45 Patients
with respiratory disease commonly have inﬂammation of
the airways and nasal passages, with a similar inﬂamma-
tory inﬁltrate in the lower and upper airways. It is now
possible to obtain repeated samples of nasal exudates
before and after nasal challenge in a relatively non-
invasive manner by techniques employing strips of nasal
synthetic absorptive matrix (SAM) inserted into the
nostril in the technique of nasosorption. Our experience
with SAM for nasosorption has been published with
regard to cytokines and chemokines in children with
allergic rhinitis,46 infants with a family history of atopy,47
and in atopic adults after nasal allergen challenge.48 In
addition, nasal epithelial curettage employing the
Rhinoprobe device is useful to obtain a pinhead of
mucosal tissue, in a technique that does not require
local anaesthesia.49 This approach has the advantages of
being safe and comfortable for the patient, yet providing
high-quality samples for transcriptomic analysis.
It is well documented that cigarette smoke is a
complex stimulus with a variety of acute and chronic
effects reported in the literature. We set out to design a
study to map the acute inﬂammatory response to smoke
in the human respiratory system and circulating cells,
with a view to providing a comprehensive molecular sig-
nature of smoking-related events in COPD. We believe
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that our model of cigarette smoke exposure comple-
ments the clinical research model of Lo Tam Loi et al.27
These approaches should lead to advances within the
ﬁeld of assessment of smoking-related immunopathol-
ogy; therefore we have taken this opportunity to share
our rationale and protocol.
Aims of the study
Our study uses non-invasive techniques for sampling, to
which ‘omic’ technology will be utilised for the compre-
hensive characterisation of this complex multifaceted
disease, with the aim of identifying disease-dependent
whole system responses to acute cigarette smoke chal-
lenge.50 The transcriptomic analysis in this study has
been designed to examine changes in gene expression
under the speciﬁc physiological condition of acute cigar-
ette smoking. This may in future allow for early interven-
tion in populations exhibiting similar gene expression
proﬁles to those observed in established COPD. This
approach also provides a diagnostic proﬁle of patients so
that treatment can be targeted and personalised.
Theoretically, it may be possible to subclassify COPD
populations, who phenotypically appear similar. In add-
ition, there is a need to analyse products of these genes,
given that transcriptomic analysis does not solely
account for the diversity in protein production and cel-
lular metabolites. A range of cytokines will be measured
before and after an acute cigarette challenge to identify
biomarkers and cell-signalling pathways associated with
COPD. Metabolic proﬁling will be used to detect the
physiological changes induced by a cigarette challenge.
Metabolic signatures may provide prognostic, diagnostic
and surrogate markers for COPD, and identify simple
non-invasive markers of drug responses for future ther-
apies.51 These investigations will be carried out on nasal
lining ﬂuid, nasal curettage, and blood, to analyse local
and systemic changes over a 5 h period following a two
cigarette challenge. Finally, it has been suggested that
patients with stable COPD have increased platelet
reactivity including circulating platelet-monocyte aggre-
gates,52 therefore, potential cardiovascular effects will
also be assessed by measuring platelet aggregation in
these patients.
Primary objective
To develop a novel cigarette challenge in vivo model
incorporating full network biology analysis of transcrip-
tomic, metabolomic and cytokine/chemokine changes
in the nose and blood of smokers with Global Initiative
for Chronic Obstructive Lung Disease (GOLD, http://
www.goldcopd.org) Stage 2 COPD, healthy smokers with
normal lung function and non-smokers, post-cigarette or
post-sham/dummy cigarette challenge.
Secondary objectives
1. To stimulate blood of smokers with GOLD Stage 2
COPD16 healthy smokers and non-smokers ex vivo
with interleukin-1β (IL-1β) and PAMPs.
2. To identify molecular biomarkers for patients with
COPD: to assist in deﬁning novel therapeutic targets,
to better stratify phenotypes and to facilitate monitor-
ing of patients.
3. To develop a cigarette smoking challenge model in
patients with COPD with an aim to utilise this in
therapeutic trials of novel therapeutic agents.
4. To carry out platelet aggregometry following stimula-
tion with speciﬁc agonists, with the aim of understand-
ing the associated pathophysiology of thrombosis and
the pharmacology of respective therapies.
METHODS
Study populations
This is a parallel group study in three groups of 12 age,
sex, ethnicity, smoking history and body mass index
matched patients (table 1):
▸ Group 1: Smokers with moderate COPD (GOLD
Stage 2);
▸ Group 2: Healthy smokers with normal lung function
(no evidence of COPD);
▸ Group 3: Healthy individuals who have never smoked.
Smokers will be current smokers, smoking at least ﬁve
cigarettes a day, with a minimum pack year history of
10 years. Current cannabis smokers or smokers with a
history of moderate or heavy cannabis use will be
excluded from the study. Non-smokers must not have
smoked a single cigarette in the 12 months prior to the
study, and must have smoked less than 100 cigarettes in
their lifetime.
Cigarette smoke challenge procedure
One to three screening visits may be required to complete
spirometry (and full lung function with gas transfer for
carbon monoxide (TLCO) in smokers), 5 slice high-
resolution CT (in smokers only) as well as laboratory safety
tests, urinalysis, ECG and physical examination.
On the cigarette challenge day, all patients will be
required to attend our unit at 9:00. They must have
fasted and refrained from smoking from 21:00 on
evening prior to the scheduled challenge. Following
baseline investigations, smokers in groups 1 and 2 will
smoke two cigarettes back to back, in a controlled envir-
onment, exhaling the smoke via their nostrils, while
non-smokers carry out normal tidal breathing over a
10 min period (ﬁgure 1).
Schedule of sampling
All patients will have nasal epithelial curettage and naso-
sorption procedures with serial blood samples (ﬁgures 2
and 3). Serial nicotine and cotinine levels will also be
taken to plot the relative smoke exposure of each indi-
vidual, as well as providing an objective measure of their
baseline smoking habit and clearance of nicotine from
their system. Full blood counts and clotting studies will
also be performed during the study to ensure patients
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Table 1 Summary of inclusion criteria and assessments in the acute cigarette smoke challenge
Inclusion criteria
Sample and assessment
parameters References
General criteria for 3 groups of patients, each of 12
individuals
▸ 45–75 years old
▸ Good general health, with no chronic illnesses
▸ No prescribed anti-inflammatory medications
(including statins)
▸ Females of childbearing potential have a negative
pregnancy test
PlasmaCigarette smoke
Correlates of exposure
▸ Nicotine
▸ Cotinine
▸ 3-Hydroxycotinine
Plasma mediators
▸ Prostanoids
▸ Metabolites
▸ Cytokines and chemokines
Whole blood ex vivo
▸ Transcriptomics
▸ TLR-agonist stimulation of
leukocytes
▸ Platelet aggregation
Nicotine54
Serum cytokines29 55–59
Serum metabolites60–62
Blood ex vivo
stimulation16 17
Smokers
▸ Current: ≥5 cigarettes/day
▸ History: ≥10 pack years
Non-Smokers
▸ Have never smoked
Nasosorption (SAM)
▸ Prostanoids: LTB4, LTC4, PGD2
▸ Metabolites
▸ Cytokines and chemokines
Group 1: Smokers with GOLD Stage 2 COPD
▸ Post-bronchodilator FEV1 50–79%; Forced expiratory
ratio <70%
▸ TLCO of <80% of normal
▸ Emphysema on 5 slice HRCT of the chest
Nasal curette
▸ Immunohistology
▸ Transcriptomics
▸ Flow cytometry
Epithelial culture
Group 2: Healthy smokers
▸ Post-bronchodilator FEV1 ≥80%; Forced expiratory
ratio ≥70%
▸ TLCO ≥80% of normal
▸ Normal 5 slice HRCT of the chest
EBC EBC33 63
Group 3: Healthy non-smokers
▸ Post-bronchodilator FEV1 ≥80%; Forced expiratory
ratio ≥70%
▸ TLCO and HRCT not done
Sputum Sputum32 64 65
COPD, chronic obstructive pulmonary disease; EBC, exhaled breath condensate; FEV1, forced expiratory volume in one second; HRCT,
high-resolution CT; SAM, synthetic absorptive matrix; TLR, toll-like receptor.
Figure 1 Cigarette smoke
challenge model (HEPA,
high-efficiency particulate air).
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have not developed any biochemically relevant illnesses
or clotting abnormalities.
Analytical methods
A representative range of non-invasive sampling methods
with associated analytical parameters is shown in table 1.
Nicotine/cotinine
Nicotine, cotinine and 3-hydroxy-cotinine will be mea-
sured in serum over the whole time course. Analysis by
capillary gas chromatography will be carried out by
Advanced Bioanalytical Service Laboratories (Welwyn
Garden City, UK).
8-Isoprostane enzyme immunoassay
Measurement of 8-isoprostane will be carried out in
both serum and nasoabsorption ﬂuid at all time points
using an 8-isoprostane enzyme immunoassay (EIA) kit
(Cayman Chemicals, Ann Arbor, Michigan, USA).
Metabolomics
In view of the multiple factors that can inﬂuence metabol-
ism, all patients are required to fast for 12 h before the
challenge begins; during this time they may only consume
water. Metabolomic proﬁling, to be conducted by
Metabolon (North Carolina, USA), measures an extensive
range of metabolites (<1000 Da) in plasma and nasal
Figure 2 Schedule of assessments (SAM, synthetic absorptive matrix, TLR, toll-like receptor).
Figure 3 Nasal sampling
methods (SAM, synthetic
absorptive matrix).
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lining ﬂuid after cigarette smoke. Metabolomic analysis will
include amino acids, carbohydrates, lipids, nucleic acids
and cofactors, molecules of redox homeostasis (eg, gluta-
thione), organic acids, and small peptides. Importantly,
many of the catabolites or biosynthetic intermediates of
these metabolites are also detected, assisting in elucidating
underlying mechanistic insight. Blood and nasoabsorption
samples will be taken at time points listed in ﬁgure 2.
Transcriptomics
Two nasal epithelial curettage samples will be taken using
a Rhinprobe prechallenge and at 300 min postchallenge.
RNA will be extracted using TRIzol (Invitrogen, Paisley,
UK). Blood will be taken at prechallenge, 20 and 300 min
postchallenge with RNA extracted using the PAXgene
Blood RNA extraction kit (PreAnalytiX GmbH,
Hombrechtikon, Switzerland). RNA will be run on an
Illumina HT12 V.4 (RefSeq Build 38 Rel 22) chip
(Illumina, San Diego, USA) with analysis carried out using
a dedicated array analysis programme GeneSpring GX
11.3 of all genes. Genes which have changed signiﬁcantly
will be identiﬁed using unpaired t tests (p<0.05) with
Benjamini-Hochberg false discovery rate correction.
Genes will be reported as 1.2-fold, 1.5-fold and twofold
increases. Quality and assessment of global transcriptome
changes will be assessed using principle component ana-
lysis in GeneSpring. Genes that have changed signiﬁcantly
will also be further explored using a dedicated pathway
analysis tool (Ingenuity Systems Pathway Analysis software,
IPA) techniques.
Ex vivo peripheral whole blood stimulation
Stimulation of whole blood taken prechallenge and at 20
and 300 min postchallenge will be performed using a
range of toll-like receptor (TLR) agonists to obtain a 24 h
dose response curve of the following ligands: LPS
(TLR4), FSL-1 (TLR6/2), Pam3CSK4 (TLR1/2), Poly(I:C)
(TLR3) and IL-1β (Invivogen, San Diego, USA). Serum
will then be removed and subsequently measured
for CXCL8 and IL-1β by ELISA (R&D Systems,
Abingdon, UK).
Platelet aggregation
For platelet aggregation studies, blood will be collected
prechallenge and at 20 and 300 min postchallenge.
Platelet rich plasma will be aliquoted into individual
wells of half-area 96-well plates coated with gelatin and
one of seven concentrations of arachidonic acid, ADP,
collagen, epinephrine, ristocetin, TRAP-6 amide or
U46619. Platelet aggregation will be determined by
changes in light absorbance, and release of thromb-
oxane (TX)A2 by ELISA.
Homogeneous time resolved fluorescence assay
Serum and nasoabsorption ﬂuid will be screened, across
all time points, for prostaglandin E2 and leukotriene B4
levels using the homogeneous time resolved ﬂuorescence
(HTRF) assay kits from Cisbio Assays (Bedford, MA).
Chemokine/cytokine immunoassay
Using a Meso Scale Discovery (MSD) immunoassay
system (MSD, Maryland, USA), a variety of chemokines,
cytokines and vascular markers will be measured in
blood and nasoabsorption samples at the time points list
above.
Statistical analyses
This is an exploratory clinical study, and we are aware
that there may not be detectable differences between
groups based on measurement of particular parameters
and the size of effects.
DISCUSSION
Clinical challenge models have been fundamental to clin-
ical research in asthma: employing inhalation of agents
such as methacholine, histamine, AMP, allergens and
occupational agents such as isocyanate and ozone. In con-
trast there has been little clinical research on the effects of
cigarette smoke in vivo involving patient studies, despite
this being the known causative agent in COPD.
Development of clinical challenge models that involve cig-
arette smoke thus have relevance to studying respiratory,
cardiovascular and neoplastic effects of cigarette smoke.
The major consideration in developing a cigarette
smoke challenge model is the ethical aspect of not encour-
aging a smoker to continue smoking, and ensuring that
maximal support is given to the individual to stop smoking
(table 2). Furthermore, we are studying patients with
mild–moderate disease, in whom there may be the possi-
bility of smoking cessation before permanent disability sets
in. Other studies have tended to evaluate later stage
disease, by which time smoking cessation has less beneﬁ-
cial effects in terms of lung function.53
A secondary consideration is ensuring the well-being
of the scientiﬁc and clinical staff involved in the study,
and minimising exposure to cigarette smoke. In our
study design, all smokers will be established in the habit
and will be actively encouraged to enter into a smoking
cessation programme immediately following their cigar-
ette challenge. Our unit has adapted a body plethysmo-
graphy box, with the addition of a carbon ﬁlter and
high-efﬁciency particulate air ﬁlter, in order to ensure
staff are not exposed to the harmful effects of smoke. If
patients were to receive their cigarette challenge outside
of the hospital, there may be confounding effects of
additional pollutants, temperature and exercise.
An important feature of the study is that smoking two
cigarettes is physiologically relevant as a challenge, and
that we were able to document levels of nicotine and
metabolites over a 5 h period. We adopted this aspect of
the study having considered the design of pharmacoki-
netic studies with nicotine delivery devices. We intend to
standardise the technique of smoking by giving two
Marlboro Red cigarettes, noting the total number of
inhalations and encouraging exhalation through the
nose. Controlled smoke exposure enables accurate
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assessment of patients’ smoking exposure by measuring
concomitant nicotine and cotinine levels. The majority
of studies do not mandate any particular smoking
restrictions prior to sampling. In this study it may be pos-
sible to formally compare nicotine exposure with levels
of induced biomarkers.
A key feature of our acute cigarette smoke challenge
model involves fasting and refraining from smoking for
12 h before and 5 h after having a controlled cigarette
smoke exposure. We also ensure that patients are not
taking any medication that may interfere with responses.
This abstinence is necessary due to the extreme sensitivity
of measurements such as metabolomics. Metabolomics
involves assessment of levels of small molecules and will
include molecules such as dietary constituents and drugs.
We take serial blood and nasal samples, in a manner
similar to a phase I pharmacokinetic study of exposure to
a single dose of drug.
The proposed study involves precision nasal sampling.
This is non-invasive, and has potential for point-of-care,
bedside and clinic monitoring. In contrast, bronchoscopy
is a research procedure only undertaken with great care in
patients with COPD. Hence, non-invasive sampling offers
great potential for future use of the model in further obser-
vational and drug studies. In contrast to many studies
looking at gene expression in cross-sectional populations of
smokers, our model has the beneﬁt of acquiring samples
longitudinally before and after a challenge with a known
trigger of the disease. This increases the power to detect
effects of the cigarette smoke challenge. We will thoroughly
evaluate the acute response to cigarettes with 10 blood and
nasal sampling time points within a 5 h challenge period.
Figure 4 Human integrated
iterative inflammometry (CVS,
cardiovascular system; TLR,
toll-like receptor; PAMPs,
pathogen-associated molecular
patterns).
Table 2 Features and ethical issues with the acute cigarette smoke challenge
Features of the model Ethical issues
Advantages
▸ Human model
▸ Acute-on-chronic inflammation
▸ Serial non-invasive sampling
▸ Combined direct measurement of biomarkers
and ex vivo stimulation
▸ Limited numbers of strictly defined patients
▸ Compare with in vivo animal models
All patients must be advised to stop smoking, and offered full clinical,
psychological and pharmacological support to carry this out
There must be no encouragement for the patient to begin or continue
smoking
Some frail patients with COPD will have difficulty fasting and refraining
from cigarettes for the morning
Clinical disease detected through the investigations must be fully
treated, regardless of participation in the study
Disadvantages
▸ Difficulty recruiting a small number of highly
defined patients
▸ Need to validate upper versus lower airway
inflammation, including tissue biopsies
▸ Signal parameters must reliably change after
acute cigarette smoke exposure
▸ Lung function and CT changes may occur after
acute smoke exposure
Some frail patients with COPD will have difficulty fasting and refraining
from cigarettes for the morning
The patient should not be taking any anti-inflammatory or confounding
therapy: therapy must not be withheld
COPD, chronic obstructive pulmonary disease.
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Given the heterogeneity of the disease and the fact
that patients with signiﬁcant comorbidities (such as car-
diovascular disease) are excluded, we are likely to be
evaluating a subpopulation of patients with mild COPD.
This is inevitable in any COPD study, but worth noting,
as it may be that this group behaves differently to those
with comorbidities.
The setting up of such studies, using a fully integrated
approach that incorporates network biology, where sam-
pling occurs after the administration of causative factors
will help us better understand the disease and design
more robust clinical trials. This type of approach is illu-
strated in ﬁgure 4 has a far ranging applications to a
number of chronic inﬂammatory diseases.
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